This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-estimates-revisions: Archive
Can GigaCloud Technology Inc. (GCT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
GigaCloud Technology Inc. (GCT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GCTPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Merit Medical (MMSI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MMSIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Research Solutions (RSSS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Research Solutions (RSSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
RSSSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Bilibili (BILI) Rating Upgrade to Buy
by Zacks Equity Research
Bilibili (BILI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BILIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Ekso Bionics (EKSO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EKSOPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BSXPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
National Health Investors (NHI) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
National Health Investors (NHI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NHIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About American Express (AXP) Rating Upgrade to Buy
by Zacks Equity Research
American Express (AXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AXPPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
CenterPoint (CNP) Upgraded to Buy: Here's Why
by Zacks Equity Research
CenterPoint (CNP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CNPNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes ITT (ITT) a New Buy Stock
by Zacks Equity Research
ITT (ITT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ITTPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Crown (CCK) Upgraded to Buy: Here's Why
by Zacks Equity Research
Crown (CCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CCKPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Does Sandisk Corporation (SNDK) Have the Potential to Rally 33.98% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34% in Sandisk Corporation (SNDK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SNDKPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Western Digital (WDC) Could Rally 25.25%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Western Digital (WDC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WDCNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TNGXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Palomar (PLMR) Could Rally 27.95%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 28% upside potential for Palomar (PLMR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PLMRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 44.9% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ENTAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think TTM (TTMI) Could Surge 30.03%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 30% upside potential for TTM (TTMI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TTMIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See Home Depot (HD) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Home Depot (HD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
HDPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Baidu Inc. (BIDU) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Baidu Inc. (BIDU) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
BIDUPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in GigaCloud Technology Inc. (GCT): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), GigaCloud Technology Inc. (GCT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
GCTPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in Commvault (CVLT) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Commvault (CVLT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CVLTPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About SkyWest (SKYW): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in SkyWest (SKYW). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
SKYWPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Look Bullish on Western Digital (WDC): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Western Digital (WDC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
WDCNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Bitfarms (BITF) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Bitfarms (BITF). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
BITFNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Sterling Infrastructure (STRL) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Sterling Infrastructure (STRL) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
STRLPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth